Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).

被引：0

作者：

Ferenci, P

Shiffman, ML

Fried, MW

Sulkowski, MS

Haeussinger, D

Zarski, JP

Goncales, F

Jensen, DM

Bonino, F

Dhumeaux, D

Blotner, S

Hoffman, J

Oliveto, J

机构：

[1] Univ Vienna, A-1010 Vienna, Austria

[2] Virginia Commonwealth Univ Med Coll Virginia, Richmond, VA USA

[3] Univ N Carolina, Chapel Hill, NC 27515 USA

[4] Johns Hopkins Ctr Viral Hepatitis, Baltimore, MD USA

[5] Univ Dusseldorf, D-4000 Dusseldorf, Germany

[6] CHU Grenoble, F-38043 Grenoble, France

[7] Univ Campinas, Campinas, Spain

[8] Rush Presbyterian St Lukes Med Ctr, Chicago, IL USA

[9] Azienda Osped Univ Pisana, Pisa, Italy

[10] Hop Henri Mondor, F-94010 Creteil, France

[11] Hoffmann La Roche, Nutley, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

716

引用

页码：351A / 351A

页数：1